RE2 Antibody

What is RE2 antibody and what makes it unique?

RE2 is a rat monoclonal antibody that specifically targets the α2 domain of murine Major Histocompatibility Complex (MHC) class I molecules. What makes RE2 particularly unique is its ability to selectively induce rapid death of activated murine lymphocytes and lymphocyte cell lines, while having no cytotoxic effect on resting lymphocytes. This cell death occurs in a complement-independent manner and differs significantly from typical apoptosis or necrosis pathways . Within just 5 minutes of exposure to RE2, target cells begin to die, making this mechanism much faster than complement-dependent cytolysis. Electron microscopy reveals that dying cells form gigantic pores on the cell surface, yet show neither DNA fragmentation nor mitochondrial swelling typically seen in classical cell death pathways .

What is the target epitope of RE2 antibody?

The RE2 antibody recognizes a monomorphic cross-reactive epitope located specifically on the α2 domain of MHC class I molecules. Studies have confirmed that this epitope is present on both K and D molecules of the MHC class I complex. This specificity is critical to understanding RE2's function, as most other murine anti-MHC class I antibodies do not possess the cytotoxic capabilities characteristic of RE2 . The unique epitope recognition enables RE2 to bind to MHC class I molecules on activated lymphocytes across different mouse strains, making it a versatile research tool.

How does RE2 antibody differ from other antibodies targeting MHC class I?

Unlike most other murine anti-MHC class I antibodies, RE2 specifically induces cell death in activated lymphocytes. This unique property stems from its recognition of a particular monomorphic cross-reactive epitope on the MHC class I α2 domain. While RE2 immunoprecipitates 90, 60, and 44 kD molecules on the cell surface of virtually all organs across mouse strains, the death-inducing effect is limited to activated lymphocytes . This suggests that while the epitope is widely present, the death mechanism requires additional activation-dependent factors present only in stimulated lymphocytes or lymphocyte cell lines.

What experimental models can be used to study RE2 antibody function?

Researchers can study RE2 antibody function using several experimental models:

• In vitro activated lymphocytes: Splenic cells activated with Concanavalin A (Con A) for 24 hours provide an effective model to study RE2-mediated cell death .

• Lymphocyte cell lines: Various murine lymphocyte cell lines are sensitive to RE2 cytotoxicity and can be used to investigate the mechanism of action .

• Fulminant hepatitis mouse models: RE2 significantly inhibits liver injury development in models with T/NKT cell activation-associated hepatitis, making this a valuable in vivo model .

• Human/mouse xeno-chimeric MHC class I gene transfectants: Human B cell lines with stable expression of human/mouse chimeric MHC class I genes have been instrumental in mapping the RE2 epitope and understanding signal transduction .

What is the molecular mechanism of RE2-induced cell death?

RE2-induced cell death involves a complex molecular pathway that differs from classical apoptosis and necrosis. The mechanism begins with RE2 binding to the α2 domain of MHC class I molecules, but interestingly, the α3 domain plays the crucial role in transducing the death signal. This signal triggers extensive aggregation of the MHC class I-integrin-actin filament system, ultimately leading to membrane blebs and pore formation .

Research has demonstrated that this death mechanism is independent of several known pathways:

• Fas-mediated pathways

• Caspase-dependent mechanisms

• Phosphoinositide-3 kinase pathways

This suggests that RE2-induced cell death represents a potentially novel pathway of cellular demise. Studies using cytoskeletal inhibitors indicate that the cytoskeleton plays a critical role in this process, as disruption of actin filaments can prevent RE2-mediated cytotoxicity .

How can researchers detect and quantify RE2-binding and subsequent cell death?

Researchers can employ several methodologies to detect and quantify RE2-binding and resulting cell death:

For RE2 binding detection:

• Flow cytometric analysis using RE2 as the primary antibody followed by FITC-conjugated mouse anti-rat immunoglobulins

• Immunoprecipitation techniques to identify the 90, 60, and 44 kD molecules that RE2 recognizes on cell surfaces

For cell death quantification:

• Trypan blue dye exclusion assay: This simple method allows for direct counting of dead cells after RE2 treatment

• Propidium iodide (PI) staining analyzed by flow cytometry: This provides a more automated and potentially more sensitive method of death detection

• Electron microscopy: To observe the characteristic membrane blebs and pores that form during RE2-induced cell death

Studies have shown that results from PI staining closely match those obtained by trypan blue exclusion, providing researchers with flexibility in their experimental design based on available equipment and expertise .

What inhibitors can block RE2-mediated cytotoxicity and what does this reveal about the mechanism?

Several inhibitors can block or reduce RE2-mediated cytotoxicity, providing valuable insights into the underlying mechanism:

These inhibitor studies reveal that the RE2-mediated death pathway is distinct from other antibody-induced death mechanisms reported for human T cells, where PI-3 kinase plays a crucial role . The effectiveness of actin cytoskeleton inhibitors particularly highlights the importance of the MHC class I-integrin-actin filament system aggregation in this unique death mechanism.

How does the activation state of lymphocytes affect their susceptibility to RE2-induced cell death?

The activation state of lymphocytes is a critical determinant of their susceptibility to RE2-induced cell death. Only activated lymphocytes and lymphocyte cell lines undergo death upon RE2 exposure, while resting lymphocytes remain unaffected despite expressing the target MHC class I molecules .

Key observations about this activation-dependent phenomenon include:

• Splenic cells must be activated (typically with Concanavalin A for 24 hours) to become sensitive to RE2 cytotoxicity .

• In vivo studies of fulminant hepatitis models show that RE2 administration specifically reduces CD69+ (activation marker) T cells and NKT cells in the liver, while having no effect on non-activated lymphocyte populations .

• Activated lymphocytes show upregulated MHC class I expression, but this alone doesn't explain the differential sensitivity, as many non-lymphoid cells with high MHC class I expression remain resistant to RE2 .

This activation-dependent selectivity makes RE2 potentially valuable for therapeutic applications targeting pathogenic activated lymphocyte populations while sparing normal resting immune cells.

What are the optimal experimental conditions for using RE2 antibody in cytotoxicity assays?

Based on published protocols, the following conditions are recommended for RE2 cytotoxicity assays:

Cell preparation:

• Target cell concentration: 10^7 cells/ml suspended in RPMI 1640 medium

• Medium supplementation: 2% de-complemented fetal calf serum

• For primary cells: Pre-activate splenic cells with Con A (2 μg/ml) for 24 hours at 37°C

Antibody conditions:

• RE2 concentration: 3 μg/ml

• Incubation time: 1 hour

• Incubation temperature: 37°C

Cell death assessment:

• Trypan blue exclusion: Count cells in triplicate

• Alternative: Propidium iodide staining with flow cytometric analysis

For inhibitor studies, add potential inhibitors 1-2 hours before RE2 addition (specific timing depends on the inhibitor used) . When optimizing these conditions for specific experimental systems, researchers should consider performing preliminary dose-response and time-course experiments.

How can researchers generate and validate human/mouse chimeric constructs to study RE2 epitope mapping?

To generate and validate human/mouse chimeric constructs for RE2 epitope mapping, researchers should follow these methodological steps:

• Design chimeric constructs:

  • Create xeno-chimeric MHC class I genes where specific domains (α1, α2, α3) are swapped between mouse and human sequences

  • Include constructs with single domain substitutions and combinations to precisely map epitope requirements

• Expression system:

  • Use human B cell lines for stable transfection of the chimeric constructs

  • This approach provides the advantage of expressing chimeric proteins in a cellular context that naturally lacks the murine epitope

• Validation of expression:

  • Confirm surface expression using flow cytometry with domain-specific antibodies

  • Verify protein size and integrity using Western blotting

• Epitope mapping:

  • Test RE2 binding to each chimeric construct using flow cytometry

  • Assess cytotoxic activity against transfectants expressing different chimeric constructs

  • Correlate binding with functional activity to distinguish between binding epitopes and domains required for signal transduction

This approach has successfully demonstrated that while the RE2 epitope resides on the α2 domain, the α3 domain plays a critical role in transducing the death signal, providing important insights into the mechanism of action .

What controls should be included when studying RE2-mediated cell death?

When studying RE2-mediated cell death, the following controls are essential to ensure experimental validity and interpretability:

Antibody controls:

• Isotype-matched control antibody (rat IgG of the same isotype as RE2)

• Other anti-MHC class I antibodies that recognize different epitopes

• Antibodies against non-MHC cell surface molecules

Cell type controls:

• Resting lymphocytes (should be resistant to RE2-mediated death)

• Activated lymphocytes (should be sensitive)

• Non-lymphoid cells expressing MHC class I (should be resistant)

• Lymphocyte cell lines (should be sensitive)

Inhibitor controls:

• Vehicle controls for each inhibitor

• Positive control inhibitors known to block other forms of cell death

• Concentration gradients to establish dose-dependent effects

Activation state controls:

• Time course of activation to correlate activation state with RE2 sensitivity

• Different activation stimuli to ensure the effect isn't specific to one activation pathway

• Activation markers (e.g., CD69) to confirm activation status

Including these controls helps distinguish RE2-specific effects from non-specific toxicity and provides insights into the specificity and mechanism of the cell death pathway.

How can researchers apply RE2 antibody in animal models of immune-mediated diseases?

Researchers can apply RE2 antibody in animal models of immune-mediated diseases following these methodological considerations:

• Model selection:

  • T/NKT cell activation-associated fulminant hepatitis has been successfully used with RE2

  • Other potential models include autoimmune diseases, transplant rejection, and lymphoproliferative disorders

• Administration protocol:

  • RE2 antibody should be administered after disease induction but before peak pathology

  • In hepatitis models, administration occurs after Con A injection

  • Dosage should be determined through preliminary dose-response studies

• Efficacy assessment:

  • Clinical scoring of disease parameters

  • Histopathological evaluation of affected tissues

  • Biochemical markers of organ damage (e.g., ALT/AST for liver injury)

  • Flow cytometric analysis of lymphocyte activation and depletion in target organs

• Mechanism investigation:

  • Compare tissue-resident vs. circulating lymphocyte populations

  • Assess lymphocyte activation status using markers like CD69

  • Evaluate T cell subsets (CD4+, CD8+) and NKT cells separately

  • Measure cytokine levels to assess immunomodulatory effects

Studies have demonstrated that in Con A-induced hepatitis, RE2 administration substantially reduces activated T and NKT cell populations in the liver and almost completely inhibits liver injury development, suggesting potential therapeutic applications .

What therapeutic potential does RE2 antibody hold for human immune-mediated diseases?

RE2 antibody demonstrates significant therapeutic potential for human immune-mediated diseases based on its unique ability to selectively eliminate activated lymphocytes while sparing resting cells. This selective targeting could provide advantages over current immunosuppressive therapies that broadly suppress immune function.

Potential therapeutic applications include:

• Autoimmune diseases: RE2 or humanized derivatives could selectively deplete pathogenic activated T cells while preserving immune surveillance functions of resting lymphocytes .

• Transplant rejection: By eliminating activated alloreactive T cells, RE2-like antibodies might prevent graft rejection with fewer side effects than current immunosuppressants .

• Allergic diseases: Targeting activated T cells involved in allergic responses could provide novel treatment approaches .

• Lymphomas/leukemias: As most lymphocyte cell lines are sensitive to RE2 cytotoxicity, similar approaches might be developed for treating lymphoid malignancies .

Future research should focus on developing humanized versions of RE2 or identifying human antibodies with similar properties that target human MHC class I molecules. Additionally, studies are needed to evaluate potential long-term effects of such therapies on immune surveillance and response to infections.

How might the RE2 mechanism contribute to our understanding of immune regulation?

The RE2-mediated cell death mechanism may represent an undiscovered pathway in immune regulation with significant implications for our understanding of lymphocyte homeostasis and immune responses:

• Novel immune regulation pathway: Beyond its established role in antigen presentation, MHC class I may participate in activation-induced cell death through mechanisms similar to RE2-mediated killing .

• Immune surveillance mechanism: The sensitivity of transformed lymphocytes to RE2 suggests that similar mechanisms might be involved in immune surveillance against lymphoid malignancies .

• Resolution of immune responses: Natural antibodies recognizing MHC class I epitopes similar to RE2 might contribute to the normal contraction phase of immune responses by eliminating activated lymphocytes.

• Cross-talk between innate and adaptive immunity: CD8+ T cells potentially recognizing monomorphic portions of class I epitopes (similar to RE2) might participate in regulating activated lymphocyte populations .

Future research should investigate whether endogenous antibodies or other molecules with RE2-like specificities exist naturally and contribute to immune homeostasis. Additionally, exploring the evolutionary conservation of this mechanism across species could provide insights into its biological significance.

What structural and molecular studies would advance our understanding of RE2's unique properties?

Several structural and molecular studies could significantly advance our understanding of RE2's unique properties:

• Crystal structure determination: Resolving the crystal structure of RE2 Fab fragments in complex with its MHC class I epitope would provide critical insights into the unique binding characteristics that enable its cytotoxic function.

• Epitope fine mapping: Identifying the precise amino acids within the α2 domain that constitute the RE2 epitope through site-directed mutagenesis and binding studies would enhance our understanding of specificity.

• Signal transduction pathway elucidation: Comprehensive proteomic and phosphoproteomic analyses of the early events following RE2 binding could identify the key signaling molecules involved in this unique death pathway .

• Mechanism of actin cytoskeleton reorganization: Live cell imaging and super-resolution microscopy studies tracking the dynamics of MHC class I, integrins, and actin filaments during RE2-induced death would illuminate the biophysical basis of membrane disruption.

• Activation-dependent factors: Comparative studies of activated versus resting lymphocytes could identify the activation-dependent factors that render only activated cells susceptible to RE2-mediated death .

These studies would not only enhance our fundamental understanding of RE2's mechanism but could also guide the development of novel therapeutic antibodies with similar selective cytotoxic properties.

How can CRISPR-Cas9 and other genetic approaches be used to further investigate RE2 mechanisms?

CRISPR-Cas9 and other genetic approaches offer powerful tools to further investigate RE2 mechanisms:

• Knockout screens: Genome-wide CRISPR knockout screens in lymphocyte cell lines could identify genes essential for RE2-mediated cell death, potentially uncovering novel components of this pathway.

• Domain engineering: CRISPR-mediated precise editing of MHC class I domains could create series of variants to pinpoint specific residues required for both RE2 binding and signal transduction within the α2 and α3 domains, respectively .

• Activation-dependent factors: CRISPR activation (CRISPRa) and interference (CRISPRi) approaches could help identify which activation-induced changes in lymphocytes are necessary and sufficient for RE2 sensitivity.

• Cytoskeletal regulators: Targeted knockout of actin cytoskeleton regulators could validate and expand upon inhibitor studies implicating the cytoskeleton in RE2-mediated death .

• In vivo models: Generation of knock-in mice with human/mouse chimeric MHC class I genes could provide valuable in vivo models to study RE2 effects in various disease contexts.

These genetic approaches would complement biochemical and structural studies, providing a comprehensive understanding of the molecular mechanisms underlying RE2's unique properties and potentially identifying novel therapeutic targets.